These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37806385)
1. Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer. Stockhammer P; Grant M; Wurtz A; Foggetti G; Expósito F; Gu J; Zhao H; Choi J; Chung S; Li F; Walther Z; Dietz J; Duffield E; Gettinger S; Politi K; Goldberg SB J Thorac Oncol; 2024 Feb; 19(2):240-251. PubMed ID: 37806385 [TBL] [Abstract][Full Text] [Related]
2. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC. Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576 [TBL] [Abstract][Full Text] [Related]
3. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP). Cardona AF; Ruiz-Patiño A; Recondo G; Martín C; Raez L; Samtani S; Minata JN; Blaquier JB; Enrico D; Burotto M; Ordóñez-Reyes C; Chamorro DF; Garcia-Robledo JE; Corrales L; Zatarain-Barrón ZL; Más L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Rodríguez J; Archila P; Bermudez M; Gamez T; Cordeiro de Lima V; Freitas H; Russo A; Polo C; Malapelle U; Perez DM; Rolfo C; Viola L; Rosell R; Arrieta O Clin Lung Cancer; 2022 Sep; 23(6):522-531. PubMed ID: 35798634 [TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083 [TBL] [Abstract][Full Text] [Related]
6. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis. Qin K; Hou H; Liang Y; Zhang X BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384 [TBL] [Abstract][Full Text] [Related]
7. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Felip E; Cho BC; Gutiérrez V; Alip A; Besse B; Lu S; Spira AI; Girard N; Califano R; Gadgeel SM; Yang JC; Yamamoto S; Azuma K; Kim YJ; Lee KH; Danchaivijitr P; Ferreira CG; Cheng Y; Sendur MAN; Chang GC; Wang CC; Prabhash K; Shinno Y; Stroyakovskiy D; Paz-Ares L; Rodriguez-Cid JR; Martin C; Campelo MRG; Hayashi H; Nguyen D; Tomasini P; Gottfried M; Dooms C; Passaro A; Schuler M; Gelatti ACZ; Owen S; Perdrizet K; Ou SI; Curtin JC; Zhang J; Gormley M; Sun T; Panchal A; Ennis M; Fennema E; Daksh M; Sethi S; Bauml JM; Lee SH Ann Oncol; 2024 Sep; 35(9):805-816. PubMed ID: 38942080 [TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393 [TBL] [Abstract][Full Text] [Related]
9. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre. Suryavanshi M; Jaipuria J; Mattoo S; Dhandha S; Khatri M Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):e451-e462. PubMed ID: 35810049 [TBL] [Abstract][Full Text] [Related]
10. Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer. Chang GC; Shih JY; Yu CJ; Chao HS; Yang CT; Lin CC; Hung JY; Hsiao SY; Wang CC; Chian CF; Hsia TC; Chen YM PLoS One; 2024; 19(5):e0303046. PubMed ID: 38753697 [TBL] [Abstract][Full Text] [Related]
11. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281 [TBL] [Abstract][Full Text] [Related]
12. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01). Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468 [TBL] [Abstract][Full Text] [Related]
13. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
14. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. Miyashita Y; Ko R; Shimada N; Mitsuishi Y; Miura K; Matsumoto N; Asao T; Shukuya T; Shibayama R; Koyama R; Takahashi K Thorac Cancer; 2021 Feb; 12(3):329-338. PubMed ID: 33219754 [TBL] [Abstract][Full Text] [Related]
15. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors. Cheng Y; Ma L; Liu Y; Zhu J; Xin Y; Liu X; Wang Y; Zhang T; Yang C; Wang S; Cui H; Zhang L; Dai J; Shao L; Lin J; Ye J; Liu H Lung Cancer; 2020 Jul; 145():63-70. PubMed ID: 32408134 [TBL] [Abstract][Full Text] [Related]
16. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. Chamorro DF; Cardona AF; Rodríguez J; Ruiz-Patiño A; Arrieta O; Moreno-Pérez DA; Rojas L; Zatarain-Barrón ZL; Ardila DV; Viola L; Recondo G; Blaquier JB; Martín C; Raez L; Samtani S; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Cuello M; Mejía S; Jaller E; Vargas C; Carranza H; Otero J; Archila P; Bermudez M; Gamez T; Russo A; Malapelle U; de Miguel Perez D; de Lima VCC; Freitas H; Saldahna E; Rolfo C; Rosell R; Target Oncol; 2023 May; 18(3):425-440. PubMed ID: 37017806 [TBL] [Abstract][Full Text] [Related]
17. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Kiritani A; Amino Y; Uchibori K; Akita T; Harutani Y; Ogusu S; Tsugitomi R; Manabe R; Ariyasu R; Kitazono S; Yanagitani N; Nishio M Thorac Cancer; 2024 Feb; 15(5):402-409. PubMed ID: 38226415 [TBL] [Abstract][Full Text] [Related]
19. Real-world data on treatment outcomes in Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma. Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]